New treatments to prevent and repair glaucoma-related eye damage
Discovery of novel disease modifying therapy for the prevention and treatment of glaucoma
Researchers are testing drug candidates that block a harmful protein interaction to help protect vision in adults with glaucoma.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas Hlth Sci Ctr NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project ID | NIH-11172534 on NIH RePORTER |
What this research studies
Glaucoma causes irreversible vision loss and current therapies mainly lower eye pressure without stopping nerve damage. This project uses 3D molecular modeling and computational pharmacology to find molecules that block the GREM1-BMP protein interaction believed to drive damage in the front and back of the eye. Identified candidates will guide lab experiments and future preclinical testing aimed at stopping optic nerve degeneration. The work is being done at the University of North Texas Health Science Center as an early step toward medicines that could better preserve vision.
Who could benefit from this research
Good fit: Adults diagnosed with glaucoma or at high risk for glaucoma would be the likely candidates for future trials that come from this research.
Not a fit: People without glaucoma or those with already-severe, irreversible vision loss are unlikely to benefit from these early-stage findings.
Why it matters
Potential benefit: If successful, this could lead to treatments that directly protect the optic nerve and better preserve vision beyond existing pressure-lowering options.
How similar studies have performed: Targeting the GREM1-BMP interaction is a novel approach and comparable disease-modifying glaucoma therapies have not yet been proven in people.
Where this research is happening
Fort Worth, United States
- University of North Texas Hlth Sci Ctr — Fort Worth, United States (Active)
Researchers
- Principal investigator: Clark, Abbot Frederick — University of North Texas Hlth Sci Ctr
- Study coordinator: Clark, Abbot Frederick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.